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T-cell-mediated hypersensitivity to metal cations is
common in humans. How the T cell antigen receptor
(TCR) recognizes these cations bound to a major
histocompatibility complex (MHC) protein and self-
peptide is unknown. Individuals carrying the MHCII
allele, HLA-DP2, are at risk for chronic beryllium dis-
ease (CBD), a debilitating inflammatory lung condi-
tion caused by the reaction of CD4 T cells to inhaled
beryllium. Here, we show that the T cell ligand is
created when a Be2+ cation becomes buried in an
HLA-DP2/peptide complex, where it is coordinated
by both MHC and peptide acidic amino acids. Sur-
prisingly, the TCR does not interact with the Be2+
itself, but rather with surface changes induced by
the firmly bound Be2+ and an accompanying Na+
cation. Thus, CBD, by creating a new antigen by indi-
rectly modifying the structure of preexisting self
MHC-peptide complex, lies on the border between
allergic hypersensitivity and autoimmunity.INTRODUCTION
The majority of ab T cell antigen receptors (TCRs) recognize
ligands in which a classical major histocompatibility complex
(MHC) protein presents a peptide secured in its peptide binding
groove. To prevent responses to self-peptides presented by
self-MHC alleles, an elaborate system of checkpoints has
evolved to control self-reactive T cells, either by deleting them
while they develop in the thymus (Kappler et al., 1987; Kisielow
et al., 1988) or by suppressing their response in peripheral or-
gans (Fontenot and Rudensky, 2004). These mechanisms steer132 Cell 158, 132–142, July 3, 2014 ª2014 Elsevier Inc.T cell responses either toward foreign peptides, e.g., those
derived from foreign pathogens, bound to self-MHC, or toward
peptides bound to foreign MHC alleles, e.g., those expressed
on grafted foreign tissues. Experimental work over several de-
cades has created a deep understanding of the nature of these
types of MHC-peptide antigens and their recognition by TCRs
(Gras et al., 2008; Marrack et al., 2008; Wilson andGarcia, 1997).
However, there are other ligands for T cells that also involve
the classical self-MHC molecules, but remain poorly under-
stood. These are often involved in inflammatory immunological
diseases. For example, despite the numerous checkpoints,
T cells can become activated in some individuals byMHC bound
to self-peptides, causing serious tissue-specific autoimmune
diseases such as type-1 diabetes, rheumatoid arthritis, and mul-
tiple sclerosis. Furthermore, T-cell-mediated allergic hypersen-
sitivities involve a wide variety of nonpeptide environmental
chemicals that include metal cations, as well as plant, industrial,
and pharmaceutical organic compounds (Fontenot and Amico-
sante, 2008; Louis-Dit-Sully and Schamel, 2014; Pichler et al.,
2006; Thierse et al., 2005). Most evidence indicates that these
agents must become associated with a self MHC-peptide com-
plex in order to elicit a T cell response, but how they bind to the
complex and how the TCR recognizes their presence is largely
unknown. A common hypothesis is that they occupy a position
on the surface of the MHCII-peptide complex and are recog-
nized directly by the TCR in a hapten-like manner, but other
mechanisms have been proposed (Illing et al., 2013; Pichler
et al., 2006).
Beryllium hypersensitivity is an example of this latter type of
T cell recognition. Because of its unique chemical properties,
industrial importance, and high toxicity, beryllium has been
extensively studied by clinicians, biologists, chemists, and phys-
icists for many years. Chronic beryllium disease (CBD) is a life-
long CD4 T-cell-mediated lung inflammatory illness, common
among certain industrial workers who handle the berylliummetal
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Figure 1. Unique Properties of the DP2
Acidic Pocket
(A) Three groups of DP2-binding peptides are lis-
ted. The top group are self-peptides that are
commonly found bound to DP2 (Dı´az et al., 2005),
but cannot present Be2+ to AV22. The middle
group contains examples from a series of mim-
otope peptides found in a positional scanning
library (Falta et al., 2013) that can present Be2+ to
AV22. The bottom group contains examples of
self-peptides that can present Be2+ to AV22,
identified by their similarity to the mimotope pep-
tides (Falta et al., 2013).
(B) Details of the acidic pocket of DP2 occupied
by each of three peptides at the top of (A),
pDRa, pA28, pRAS. Ribbons: DP2a, cyan; DP2b,
magenta. Wireframe with CPK coloring: peptide
and side chains of DP2 b26E, b68E, and b69E.
Potential H-bond/salt bridges, green lines.
See also Figure S1 and Table S1.(Dai et al., 2013). It is highly associated with certain human class
II MHC (MHCII) alleles, especially HLA-DP2 (DP2), that have a
glutamic acid at position 69 of the b chain (b69E). The active
agent in the disease is the Be2+ cation. Since the Be2+ cation
has such a high-charge density, it immediately forms higher-or-
der complexes in biological solutions involving electron donors
such as water, hydroxyl ions, carbonate, phosphate, etc. (Ever-
est, 1964; Sutton and Burastero, 2003). It has been suggested
that b69E captures such a Be2+ containing complex which is
then recognized on the DP2 surface by CD4 T cells, but the
structural details of this complex or its recognition are unknown.
Numerous Be2+-specific CD4 T cell lines and clones have
been isolated from the lungs of CBD patients that express DP2
(Bowerman et al., 2011; Falta et al., 2013; Fontenot et al.,
1999; Saltini et al., 1989). In vitro, these T cells respond to
Be2+, but not other metal cations, presented by autologous or
other DP2-expressing antigen presenting cells (APCs). This
response is dependent not only on Be2+ and DP2, but also on
particular DP2 bound self-peptides (Falta et al., 2013). Using
positional scanning peptide libraries, we recently identified aCell 158, 132set of peptide mimotopes, and subse-
quently a set of related natural self-pep-
tides, that can complete the DP2/pep-
tide/Be2+ ligand for one of these T cells,
AV22, as well as other T cells from the
same patient or from nonrelated DP2+ pa-
tients (Falta et al., 2013). Here, we report
the functional, biophysical, and structural
properties of the AV22 TCR/DP2/peptide/
Be2+ quaternary complex and define the
changes that occur in the DP2-peptide
complex upon Be2+ binding that enable
TCR recognition. Remarkably, the struc-
tures show that the immunogenic form
of beryllium is not a beryllium containing
compound, but rather the Be2+ cation it-
self, which is buried within the DP2-pep-
tide structure. The TCR does not interactdirectly with the Be2+ ion, but instead recognizes changes in
the surface of DP2/peptide complex surface induced by the
internally bound Be2+.
RESULTS
Common Features of DP2-Peptide Complexes
Listed at the top of Figure 1A are three peptides that are well-rep-
resented among those naturally bound to DP2 (Dı´az et al., 2005),
yet do not present Be2+ to the Be2+-specific TCR, AV22, or any
other Be2+ reactive T cell tested so far (Dai et al., 2010; Falta
et al., 2013). We previously solved the structure of one of these
nonpresenting peptides, DRa, bound to DP2 (Dai et al., 2010).
We have now solved the structures of DP2 bound to the other
two nonpresenting peptides, A28 and RAS. Although they do
not present Be2+, the structures of these complexes reveal two
common features of DP2 that are relevant to Be2+ presentation.
First, in all three structures the important b69E lies in an acidic
pocket that includes two other DP2 acidic amino acids, b26E
and b68E (Figure 1B).We have shown previously that these three–142, July 3, 2014 ª2014 Elsevier Inc. 133
amino acids are important in Be2+ presentation (Dai et al., 2010).
Second, the wide gap (11.0 A˚) between the peptide backbone
and the DP2 beta chain alpha helix that we reported previously
for the DP2-DRa structure is also present in the DP2-A28
(10.3 A˚) and DP2-RAS (10.5 A˚) structures (Figure S1 available
online). This gap is several angstroms wider than generally
seen in the structures of other MHCII alleles (Dai et al., 2010).
Consequently, this extra space frees the side chains of the p4
and p7 amino acids that flank the acidic pocket to assume ro-
tamers that can enter the pocket. For example, in the A28 struc-
ture the p4K interacts with DP2 b26E and b69E. Similarly, in the
RAS structure, p4Q and p7H interact with DP2 b26E and b69E,
respectively. These observations suggested to us that, depend-
ing on the peptide sequence, the particular amino acids at p4
and p7 of the peptide might influence the ability of the pocket
to capture Be2+ from the solvent. We therefore set out to test
this idea.
Unique Properties of the Peptides that Allow Be2+
Presentation by DP2
Some of the previously identified mimotopes and self-peptides
that, when bound to DP2, allow presentation of Be2+ to AV22
and related T cells are also listed in Figure 1A in the middle
and bottom sections, respectively (Falta et al., 2013). These
Be2+ presenting peptides all share a p4D and p7E. Given the
results described above, we hypothesized that these two acidic
amino acids interact with DP2 to capture and coordinate Be2+
such that the combination is recognized by Be2+-specific
TCRs. Therefore, we investigated their role in the properties of
mimotope-2 (M2) bound to DP2 in the presence and absence
of Be2+.
We prepared two mutated forms of the DP2-M2 complex:
DP2-M2(NQ), in which the p4D and p7E of M2 were changed
to the nearly isomorphous amides, N and Q and DP2(b69K)-
M2, in which the DP2 high-risk amino acid for CBD, b69E, was
changed to lysine, the amino acid found at position b69 in
HLA-DP4, a DP allele negatively associated with CBD (Maier
et al., 2003). We assessed the ability of the wild-type and
mutated complexes to stimulate the AV22 T cell transfectoma
with or without Be2+ (Figure 2A). As a negative control, we
used an irrelevant HLA-DR52c-peptide complex (Yin et al.,
2012). None of the complexes stimulated AV22 in the absence
of Be2+. In the presence of Be2+, AV22 responded strongly to
the DP2-M2 complex, but there was no response to either of
the mutant DP2-M2 complexes or the control DR52c complex,
indicating the importance of b69E and the requirement for
the carboxylates of the p4D and p7E side chains for Be2+
presentation.
We confirmed these results with surface plasmon resonance
TCR binding experiments. Equal amounts of the soluble, bio-
tinylated DP2-M2, or the mutant complexes were captured in
the flow cells of a BIAcore streptavidin BIAsensor chip and
tested for binding of soluble AV22 TCR. In the absence of Be2+
the unmutated DP2-M2 complex failed to bind the TCR (Fig-
ure 2B, left). As we previously have demonstrated (Falta et al.,
2013), in the presence of Be2+ the same complex bound AV22
TCR with high affinity (3–6 mM) and first order kinetics (Figures
2B and 2C). In contrast, neither the DP2-M2(NQ) nor the134 Cell 158, 132–142, July 3, 2014 ª2014 Elsevier Inc.DP2(b69K)-M2 mutated versions of the complex, with or without
Be2+, bound the AV22 TCR (Figure 2D). Taken together, these
results confirm our previous conclusion that the acidic properties
of p4D, p7E, and b69E are essential for Be2+ presentation.
Finally, using differential scanning fluorimetry (Niesen et al.,
2007), we determined the effect of Be2+ on the thermal stability
of various MHCII-peptide complexes, using the binding of the
fluorescent dye, SYPRO Orange, to follow protein denaturation
(Figure 2E). We examined four DP2-peptide complexes, two
with peptides, M2 and Plx4, that could present Be2+ to AV22
(Figure 1A), onewith the self-peptide, A28, that could not present
Be2+, and finally the DP2(b69K)-M2 mutant described above. As
a negative control, we used the well-studied mouse MHCII-pep-
tide complex, IAb-3K (Liu et al., 2002). The stability of each
complex was defined by the melting temperature (Tm), i.e., the
temperature causing the half maximal increase in SYPRO Or-
ange fluorescence. In the absence of Be2+, the Tm of the control
IAb-3K complex, as well as those of the DP2-A28, DP2-M2, and
DP2-Plx4 complexes ranged from 54.4C–62.5C. As expected,
the addition of Be2+ had little effect on the Tm of IAb-3K or the
DP2-A28 complex. However, addition of Be2+ raised the Tm of
DP2-M2 and DP2-Plx4 complex to more than 70C, a >10C
increase. Unexpectedly, in the DP2(b69K)-M2 complex, substi-
tution of lysine for the critical DP2 b69E led to a similar increase
in stability, whether or not Be2+ was added. This result suggests
that the positively charged ε-amino group of b69K might substi-
tute for Be2+ in the stabilization of the complex, but could not
create the ligand recognized by AV22 (Figure 2A).
These findings strongly implicated the cluster of acidic amino
acids from both DP2 and the presenting peptides as the site of
Be2+ binding, since both were involved in stabilizing the complex
in the presence of Be2+ and both were needed to create a Be2+-
dependent ligand that could be recognized by the AV22 T cell.
Be2+ and an Accompanying Na+ Cation Bind Internally in
the Acidic Pocket of DP2-M2
To understand the nature of the Be2+ moiety that binds to DP2-
M2, how the DP-M2 structure changes after binding Be2+, and
how the AV22 TCR recognizes these changes, we solved the
structures of DP2-M2 in the absence of Be2+ and of the DP2-
M2-Be2+ complex bound by the AV22 TCR (relevant methods
and statistics for data collection and refinement for all structures
reported in the paper are given in the Extended Experimental
Procedures and Table S1). We first compare the structure of
the acidic pocket in the free DP2-M2 complex to that in the
Be2+ loaded DP2-M2 bound by the AV22 TCR.
In the DP2-M2 complex, electron density in the acidic pocket
clearly shows that the side chains of p4D and p7E have entered
the acidic pocket, both prior to (Figure 3A) and after (Figure 3B)
Be2+ addition. However, their side chain configurations and
those of the other acidic amino acids in the pocket have changed
in the presence of Be2+, indicating that Be2+ has been captured
within the pocket. To deduce the position of the Be2+, we relied
on previous analyses of numerous small molecule structures
containing Be2+ coordinated by oxygens, as well as larger pro-
tein structures in which an aspartic acid carboxylate has
captured BeF3. The coordination chemistry of Be
2+ is well docu-
mented in these studies (Everest, 1964; Keizer et al., 2005). The
A B C D
E
Figure 2. The Acidic Pocket Is Required for the Be2+-Dependent Functional and Biophysical Changes in DP2-Peptide Complexes
(A) Equivalent amounts of biotinylated MHCII-peptide complexes (DP2-M2, DP2-M2(NQ), DP2(b69K)-M2, and HLA-DR52c-pHIR) were immobilized in separate
culture wells and used to stimulate the AV22 transfectoma T cell with or without various concentrations of BeSO4. IL-2 secretion was assessed at 24 hr. The
experiment was repeated with equivalent results.
(B) Biotinylated DP2-M2 (2,000 RU) was captured in a flowcell of an SA-biosensor chip in a BIAcore 2000 instrument. Various concentrations of soluble AV22
TCR were injected for 140 s through the flowcell, before and after loading of the immobilized DP2-M2 with Be2+. The surface plasmon resonance signal (RU) was
followed both during and after the injection and the binding kinetics analyzed with BIAcore BIAevaluation 4.1 software. The experiment was repeated four times
with similar results.
(C) The plateau equilibrium RU data in (B) were used to create a Scatchard plot. The dissociation constant (KD) and regression coefficient (R) were calculated from
the linear least-squares fit to the data.
(D) Same as (B) except that biotinylated DP2-M2(NQ) andDP2(b69K)-M2were immobilized in separate flowcells. Only data for the injection with 5 mMAV22 TCR is
shown. The experiment was repeated with similar results.
(E) The thermal stability of the series of soluble MHCII-peptide complexes shown was assessed in the presence or absence of Be2+ using differential scanning
fluorimetry with the fluorescent dye SYPRO orange. Themelting temperature (Tm) was defined as the temperature needed to achieve the half maximal increase in
fluorescence. Results are pooled and averaged from six experiments. Each melting curve was performed at least three times among the experiments.high-charge density of Be2+ creates four short, semicovalent
bonds (1.5 to 1.7 A˚) to its ligands distributed in a tetrahedral
arrangement with bond angles of 110. Because there are
only two electrons in Be2+, in most X-ray structures the position
of the Be2+ in the complex cannot be deduced from the Be2+
electron density alone, but rather from the position where the
electron densities of its ligands converge.
Based on the genetic, mutational, functional, and biophysical
data, we clearly predicted that a carboxylate oxygen from b69E
would be one of these ligands. In the absence of Be2+, separate
densities were seen for each of the five carboxylates in the acidic
pocket (Figure 3A), but their oxygens were not in the correct po-
sitions to join with b69E in tetrahedral Be2+ ligation. However, in
the presence of Be2+, the density for the carboxylates converged
(Figure 3B) and carboxylate oxygens from p4D and b26E were
brought into position to ligate an b69E captured Be2+ with the
expected Be-O bond lengths of 1.6–1.7 A˚ and O-Be-O bondangles of 110–115 (Figure 3C). Movement of the p7E carbox-
ylate placed a fourth oxygen at an angle such that it could be
the fourth Be2+ ligand. However, the 3 A˚ distance from this
oxygen to the Be2+ is too far to allow a conventional Be-O
bond (Figure 3C). Because there are no published structures of
Be2+ coordinated solely by protein amino acid carboxylates,
we cannot say if this type of Be2+ ligation in a protein is unusual,
although small molecules containing a Be2+ with only three li-
gands do exist (Diyabalanage et al., 2008), and deviations from
ideal ligation have been seen for other cations incorporated
into protein structures (Evans, 2007; Harding, 2002). Therefore,
this positioning of Be2+ among these four oxygens was consis-
tent both with its known coordination chemistry and with our
data with mutations of b26E b69E, p4D, and p7E presented
here and previously (Dai et al., 2010; Falta et al., 2013).
The Fo-Fc electron density map of the complex suggested the
presence of another larger atom(s) in the acidic pocket inCell 158, 132–142, July 3, 2014 ª2014 Elsevier Inc. 135
Figure 3. Be2+ and an Accompanying Na+ Cation Captured in the Acidic Pocket Are Shielded from the Solvent
(A and B) View from above looking into the acidic pocket of DP2-M2-Be2+ with the side chains of b26E, b68E, b69E, p4D, and p7E shownwith 2Fo-Fc (1s) electron
density before (A) and after (B) capture of Be2.
(C) Overlay of the carboxylates of b26E, b69E, p4D, and p7E before (carbon, blue) and after (carbon, white) binding of Be2+. Arrows show the Be2+-induced
movement of the relevant carboxylate oxygens. Be2+ (green) is modeled within the cluster of oxygens based on small molecule structures of Be2+ coordinated by
carboxylates (Alerghi et al., 1999; Schmidbaur et al., 1991; Schmidt et al., 1997) and the Be-O bond lengths are shown.
(D) Unaccounted for electron density in the Fo-Fc (6s) map in the acidic pocket of DP2-M2-Be2+.
(E) A Na+ cation is shown modeled into Fo-Fc density of (D). Distances of the Na+ from Be2+ and from oxygens of the carboxylates of b68E, b69E, p4D, and p7E
and the backbone carbonyl oxygen of p5L are shown.
(F) A view looking through the M2 peptide toward the DP2 b1 alpha helix showing the water accessible surface of the DP2-M2-Be2+ colored by the contributing
atoms (oxygen-red, carbon-white). The surface contributed by the DP2 a1 alpha helix has been clipped to reveal the carboxylates of the five acidic amino acids in
the pocket along with Be2+ and Na+ among which only b68E, p4D, and p7E are surface accessible.addition to Be2+ (Figure 3D). We considered that this density
might be due to an hydroxyl ion acting as a fourth Be2+ ligand,
but the position and distance of this oxygen in relation to Be2+
would be inconsistent with Be2+ coordination geometry. It is
more likely that this density was due to a second cation, often
seen attracted to Be2+ complexes because of the net negative
charge of the ligated Be2+. We could not determine the nature
of this cation from the density alone. However, no ordered cation
was seen in the structure of the free DP2-M2 complex in the
absence of Be2+ (Figure 3A), and the mother liquor used in crys-
tallizing the AV22-DP2-M2-Be2+ complex contained 300 mM
Na+ as the only cation. Therefore, by default, we modeled Na+
into this density (Figure 3E). Placed in this position, the Na+ is
surrounded by oxygens from the carboxylates of p4D, p7E,
b68E, and b69E and from the carbonyl of the p5L backbone,
consistent with the analyses of Harding (2002) documenting a136 Cell 158, 132–142, July 3, 2014 ª2014 Elsevier Inc.predilection for Na+ to interact with up to eight oxygens in pro-
teins. In order to accommodate this Na+, the carboxylate of
b68E has been pushed up on the surface of the DP2-M2 complex
and undergone a 90 rotation, bringing its negatively charged
oxygen into alignment with the Na+ cation.
While our data support the conclusion that the cation
captured in this crystal is Na+, our structure here does not rule
out the possibility that, in vivo or tissue culture, cations other
than Na+ might occupy this position and may even complete
the TCR ligand. Mg2+ would be a possibility, but so would
Ca2+ and K+, also abundant in biological fluids and tissue culture
media.
In summary, upon Be2+ binding, the DP2-M2 acidic pocket
undergoes a conformational rearrangement in order to capture
the Be2+ and an accompanying Na+ cation through a network of
interactions via the b69E carboxylates and other DP2 and M2
Table 1. Contacts between AV22 TCR and DP2-M2-Be2+
AV22 TCR Contacts to DP2-M2-Be2+ DP2-M2-Be2+ Contacts to AV22 TCR
V Domain CDR Loop Amino Acid
No. of Atom to Atom Contacts to
Ligand Amino Acid
No. of Atom to Atom Contacts to
DP2a M2 DP2b Va Vb
Va 1 30Y – 6 45 DP2a 55E 7 –
32S – – 3 57Q 4 –
2 49K – – 1 58G 4 –
51T – – 3 65I – 4
52K – – 2 M2 1F 1 –
3 95Y – 59 – 2W 54 –
97G 3 – – 3I 24 –
98A 12 11 – 5L 11 10
99G – 14 – 6F – 4
101Y – – 19 7E – 6
Vb 1 30R – 10 – 8T – 17
2 50F – 1 – DP2b 58Y – 3
55R – 3 – 62Q – 4
3 95L – – 12 64D – 22
96A – – 10 65I – 4
97Q 4 23 5 67E 2 –
98G – – 6 68E – 20
99G 1 71A 2 –
100E – – 10 74D 4 –
101T – – 9 75R 24 8
103Y – – 8 78R 15 –
79H 20 –
82E 6 –
Total 19 127 134 178 102
See also Tables S1 and S2.oxygens, thus dramatically increasing the thermal stability of
the complex. There are two unexpected features of this
complex. First, the Be2+ moiety captured is the Be2+ cation it-
self, not a larger complex of Be2+ already partially ligated by
solvent-derived electron donors (water, hydroxyl, carbonate,
etc.). This answers a long-standing question in this field
regarding the chemical form of Be2+ that is captured by DP2.
Second, both the Be2+ and Na+ are not accessible on the
surface of the complex, so that the AV22 TCR must recognize
some change in the complex surface induced indirectly by
the Be2+ and Na+ (Figure 3F). Therefore, we analyzed the
interface between the AV22 TCR and the DP2-M2-Be2+ com-
plex, especially in the region over the inaccessible Be2+ and
Na+. A summary of the atom-to-atom contacts and the com-
plete details of the contacts are listed in Table 1 and Table
S2, respectively.
General Features of the AV22 TCR Binding to the DP2-
M2-Be2+ Ligand
Typically, TCRs bind to MHCII ligands in a diagonal mode that
places the CDR3 loops of the V domains over the peptide, while
CDR1 and CDR2 loops make multiple interactions with the
MHCII helices (see Marrack et al., 2008; Wilson and Garcia,1997). The AV22 TCR also takes this diagonal orientation on
the DP2 complex (Figure 4A), but there are some unusual fea-
tures of the interface. The TCR is tilted toward the DP2 beta
chain helix (Figure 4B) resulting in extensive contact with the
entire length of the M2 peptide and DP2 beta chain helix, at
the expense of the DP2 alpha chain helix (Figure 4C; Table 1).
Furthermore, atypically, the hypervariable CDR3 loops of the
TCR dominate the binding (Figure 4D; Table 1), providing almost
three quarters of the contacts with the ligand. The CDR1 and
CDR2 loops of the TCR contribute little to the interface with
the exception of a single TCR Va amino acid, CDR1 a30Y, which
binds extensively to the C-terminal end of DP2 b chain helix
(Table 1; Figure 4C). The focus of the AV22 TCR on the bound
peptide and DP2 beta chain helix is consistent with our previous
extensive mutational analysis of DP2 and the AV22 TCR (Bill
et al., 2005; Bowerman et al., 2011). Despite this tilted confor-
mation, the footprint of the AV22 TCR on DP2-M2 involves
280 atom-to-atom contacts (Table 1) and covers 1,288 A˚2,
well within the range typically seen for CD4 T cell TCR contact
with MHC-peptide ligands. Moreover, the TCR has a KD of
5 mM when binding to the complex (Falta et al., 2013) (Figures
2B and 2C), among the highest affinities seen for a TCR from a
CD4 T cell.Cell 158, 132–142, July 3, 2014 ª2014 Elsevier Inc. 137
Figure 4. Skewed Docking of the AV22 TCR on the DP2-M2-Be2+
Complex
(A) View from above showing the diagonal docking of the six AV22 TCR CDR
loops over the DP2-M2-Be2+ complex.
(B) View looking down the peptide binding groove from the peptide C terminus
showing the tilt and shift of the AV22 TCR CDR loops toward the DP2 beta
chain helix.
(C)Water accessible surface of the DP2-M2-Be2+ complex, DP2a (cyan), DP2b
(magenta), and M2 (yellow). The footprint of the AV22 TCR on the complex is
shown with darker versions of the same colors. Complex atoms were defined
to be part of the footprint if they were within 4.5 A˚ of a TCR atom.
(D) The parts of the footprint created by the AV22 TCR CDR3a (blue) and
CDR3b (red) are shown.
See also Tables S1 and S2.
Figure 5. Interaction of AV22 VbCDR3 with the Surface of DP2-M2
above the Be2+ Binding Site
(A) A wireframe representation is shown of the backbone of the AV22
TCR VbCDR3 loop and the side chain of Vb97Q interacting with the surface of
DP2-M2. Colored as Figure 4C with b68E red, p7E orange, and p4D in green.
(B) The orientation of the side chain carboxylate of DP2 b68E between the
VbCDR3 loop of the AV22 TCR and the internal Na cation is shown. Potential
H-bond/salt bridges are shown as green lines.
(C) The response of AV22 without or with various concentrations of BeSO4
presented by the wild-type DP2-M2 complex or the complex mutated at b68E
to glutamine or alanine. The experiment was repeated with similar results.
(D) Interactions of the carboxamide of Vb CDR3 97Q with the M2 peptide are
shown. Potential H-bonds are shown as green lines.
See also Figure S2 and Table S2.TheAV22 TCR Interacts with Changes in DP2-M2
Induced by Be2+
As predicted by their internal positions in the ligand structure,
the sheltered Be2+, Na+, b26E, and b69E have no direct TCR
contact (Table S2), but there is a large area of TCR contact,
especially via VbCDR3, with the surface of DP2-M2 that includes
the re-positioned b68E carboxylate, as well as surrounding DP2
and M2 amino acids (Figures 4D and 5A; Tables 1 and S2). The
repositioned b68E carboxylate bridges the hidden Na+ and Vb
CDR3 via an H-bond to the backbone N of Vb 98G (Figure 5B;
Table S2).
In a previous study, we showed that mutation of b68E to A
virtually eliminated the Be2+ response of a line of lung T cells
(containing T cells bearing various TCRs) from the patient that
provided the AV22 T cell. In these experiments, the presenting
DP2 was on the surface of an APC line and contained the usual
array of naturally processed self-peptides (Dai et al., 2010).
Therefore, we tested the effect of mutating b68E on the recogni-
tion by the AV22 of our soluble DP2, in this case uniformly occu-138 Cell 158, 132–142, July 3, 2014 ª2014 Elsevier Inc.pied by M2 and Be2+. We tested the mutation of b68E to A
(eliminating its side chain) but also to Q (eliminating only the
negative charge of its carboxylate). The b68E to Q change
completely eliminated the ability of DP2-M2 to present Be2+ to
AV22 (Figure 5C) or to be bound by the soluble AV22 TCR in
the presence of Be2+ (Figure S2). However, in this case, mutation
of b68E to A only partially reduced the response (Figure 5C). It
also decreased by 2-fold the half-life of the AV22 TCR complex
with DP2-M2-Be2+, but not the overall affinity of the TCR for
the ligand (Figure S2). These results suggest that the direct inter-
actions of the VbCDR3 with the side chain of b68E contribute to,
but are not required for, a response, depending on the specific
TCR and peptide presenting the Be2+. However, more impor-
tantly, when this side chain is present, the Be2+, the accompa-
nying Na+ and the negative charge of b68E carboxylate may all
be required for the proper realignment of the carboxylate.
Removing the b68E charge by its mutation to Q must somehow
untether the side chain to interfere with TCR binding.
Another area of extensive interaction of the Vb CDR3 loop is
via the carboxamide of the Vb 97Q side chain, which lies across
the peptide making substantial van der Waals’ and H-bond
Figure 6. Specific Changes in the Electrostatic Surface Potential of
the DP2-M2 Complex Caused by Binding Be2+/Na+
(A and B)Water accessible surface of the DP-M2 complex in the absence (A) or
presence (B) of Be2+ and Na+, colored by the electrostatic surface potential
(red, negative; blue, positive). Area overlaying the acidic pocket is circled.
(C) The interaction of the b69K lysine ε-amino group in the DP2(b69K)-M2
mutant structure with amino acids in the acidic pocket is shown. Potential
H-bond/salt bridges are shown as green lines.
(D) The electrostatic surface potential of the DP2(b69K)-M2 mutant complex is
shown as in (A).
See also Tables S1 and S2.contacts with theM2 peptide (p5L, p6F p7E, and p8T) (Figure 5D;
Tables 1 and S2). These aspects of the interaction agree with our
previous mutation analysis of the AV22 TCR, where an alanine
scan of the Vb CDR3 loop showed that the side chain of b97Q
was required for Be2+ recognition (Bowerman et al., 2011).
In addition to the conformational changes, the most dramatic
difference between the DP2-M2 complex before and after Be2+
and Na+ binding is the change in the predicted electrostatic sur-
face potential (Figures 6A and 6B). In the absence of Be2+ and
Na+, the surface potential in the entire region around the acidic
pocket is very negative, but it becomes substantially neutralized
by the addition of the positively charged Be2+ and Na+ to the
acidic pocket. This electrostatic difference would be expected
to influence the ability of the Vb CDR3 loop to approach and
interact with this surface. As mentioned above, we can not rule
out that, in vivo or tissue culture, the cation accompanying
Be2+ might be an abundant divalent cation, such as Mg2+ or
Ca2+, rather than Na+. In this case, we would predict that thenegative electrostatic surface potential would be reduced even
further.
The structure of the DP2(b69K) complex supports the impor-
tance of these surface changes induced by Be2+ and Na+
binding. This mutated complex cannot present Be2+ to AV22
(Figure 2A), but its thermal stability is equal to that of the
wild-type complex in the presence of Be2+ (Figure 2E). In the
structure, the b69K positively charged ε-amino group has
been drawn into the acidic pocket in a position similar to the
Be2+ in the wild-type structure and is involved in a network of
H-bonds and salt bridges to p4D, p7E, DP2 b26E, and the pep-
tide backbone (Figure 6C), accounting for the thermal stability
of the complex and predicting that this complex could not
bind Be2+. However, there is no evidence of a captured cation
and the b68E side chain is aligned similarly to that of the DP2-
M2 complex without Be2+. Furthermore, the predicted electro-
static surface potential of the mutant complex is only slightly
reduced by the lysine single positive charge (Figure 6D). These
differences from the DP-M2-Be2+ complex most likely explain
the lack of recognition by AV22.
In summary, after binding to DP2-M2, Be2+ and Na+ are not
exposed for TCR interaction, but rather induce both a reduction
in the electrostatic surface potential and a subtle change in sur-
face topology of the DP2-M2 over the cation binding site where
the AV22 TCR Vb CDR3 interacts. Our data indicate that both of
these changes probably contribute to creation of the AV22
ligand, but we cannot at present estimate the relative contribu-
tions of the two alterations.
DISCUSSION
Dozens of structures of TCRs interacting with MHC-peptide
ligands have been published, and there are a number of struc-
tures detailing how TCRs bind to nonclassical MHC molecules
specialized to present particular nonpeptide or peptide ligands
(http://www.imgt.org/3Dstructure-DB/). However, T-cell-medi-
ated hypersensitivity to nonpeptide environmental agents such
as drugs, plant products, and metal cations are widespread in
the human population. There is very little known structurally
about how these agents become associated with MHC mole-
cules and how T cells recognize their presence. The work pre-
sented here answers a long-standing question about how a
metal cation, in this case Be2+, becomes associated with a self
MHC-peptide complex to create the ligand for a pathogenic
T cell.
The most common hypothesis for how nonpeptide moieties
are recognized by T cells has been that they act as haptens,
i.e., they become associated with or covalently bound to the
surface of an MHC-peptide complex and offer a new site for
TCR interaction, in the same way that a mutation in one of the
upwardly pointing amino acids of the MHC or bound peptide
would create a new antigen. Earlier studies with T cell reactivity
to MHC-peptide complexes modified with chemically reactive
forms of trinitrophenol and fluorescein or the urushiols produced
by plants such as poison ivy were interpreted this way (Kalish,
1990; Martin and Weltzien, 1994).
Our X-ray diffraction data, as well as mutational and biophys-
ical results, show that Be2+ is clearly not working in this way,Cell 158, 132–142, July 3, 2014 ª2014 Elsevier Inc. 139
but, rather, becomes part of the internal structure of the
MHC-peptide complex, indirectly causing structural and bio-
physical changes on the surface of the complex that are now
recognized by the T cell. The Pichler group has argued for
some years for a concept they term ‘‘pharmacological interac-
tion with immune receptors’’ or the ‘‘p-i’’ concept (Pichler
et al., 2006), in which drugs can interact with TCRs or MHC-pep-
tide complexes to promote an interaction without necessarily
placing the drug at the interface between the two. Perhaps the
most dramatic evidence for this phenomenon is seen in the se-
vere allergic response to the drugs, abacavir and carbamaze-
pine. These reactions are strongly associated with particular
MHCI HLA-B alleles (Illing et al., 2013). Recent structural and
biochemical data (Illing et al., 2012) indicate that, unlike Be2+,
these drugs work by binding inside the MHC peptide binding
groove to drastically change the repertoire of self-peptides
bound, generating a robust CD8 T cell response similar to an
allo-MHC response.
In our studies here, Be2+ also binds internally within the pep-
tide binding groove of DP2 without becoming part of the TCR
interface, yet it creates the TCR ligand without changing the
DP2 bound peptide. Also supporting this conclusion, is our
previous study using DP2+ antigen presenting cells to present
Be2+ to CBD T cells. To show that Be2+-dependent loading of
new peptides into DP2 was not required, we fixed the antigen
presenting cells prior to Be2+ exposure without compromising
the T cell response to Be2+ (Fontenot et al., 2006). Neverthe-
less, the DP2 complex becomes much more stable in the pres-
ence of Be2+ and the appropriate mimotope or self-peptide
(Figure 2E). Therefore, it is possible that the continuous
presence of Be2+ in vivo in CBD may promote the loading
or stability of peptides that present Be2+ in the MHCII endoso-
mal peptide loading compartment, eventually skewing the
lung DP2-bound peptide repertoire toward Be2+-presenting
peptides.
The nature of the Be2+ containing compounds recognized
by the immune system has been discussed for many years.
Because of its ability to form higher-ordered complexes in
aqueous solutions (Everest, 1964; Sutton and Burastero, 2003),
it was natural to consider that the Be compound captured
by DP2 b69E might already contain multiple Be ligands, thus
creating a surface-exposed hapten-like moiety for T cell recog-
nition. Our data presented here clearly shows that this is not
the case. Rather, it is the Be2+ cation itself that is captured by
the DP2-M2 complex. This explains why individual T cell clones,
such as AV22, can be activated by a wide variety of soluble
Be-containing compounds (Dai et al., 2010). The Be2+ binding
acidic pocket in the DP2-peptide complex appears to compete
extremely well with other potential ligands for Be2+.
AV22 and related T cells found in the lungs of multiple CBD
patients respond to Be2+ presented by DP2 containing a variety
of related self- or library-generated peptides (Falta et al., 2013)
(Figure 1A). The common elements in all of the peptides, besides
a DP2 binding motif, are p4D and p7E. However, these peptides
do not satisfy all Be2+ reactive T cells (Falta et al., 2013). Given
the extensive interaction of the AV22 TCR with areas of the
DP2-M2 surface away from the DP2 acidic pocket (Table 1), it
is likely that these other T cells will require TCR contact with140 Cell 158, 132–142, July 3, 2014 ª2014 Elsevier Inc.different peptide amino acids in these other areas. However,
we predict that they will have to retain this p4D/p7E or a similar
acidic motif in order to effectively capture Be2+.
CBD is a particularly dramatic example of blurring the
line between T cell allergic hypersensitivity and autoimmunity.
Similar to many of the well-studied autoimmune diseases,
CBD risk is tightly associated with certain MHCII alleles, in this
case with an existing DP2-self-peptide complex that has been
subtly changed by the internally bound Be2+. As structural
information begins to accumulate for the actual targets of
autoimmune diseases, enzymatic posttranslational modifica-
tions (Cordova et al., 2013; Scally et al., 2013; Sollid and Jabri,
2011) and organ-specific peptide processing have been impli-
cated in generating the relevant ligands (Crawford et al., 2011;
Mohan and Unanue, 2013; Stadinski et al., 2010). These are
often not recognized by the autoimmune T cells directly, but
instead affect the way the peptide binds to MHCII. In the same
way, Be2+ binding could be thought of as a special form of
‘‘posttranslational modification’’ that converts a self-MHCII-pep-
tide complex to which the immune system is tolerant into an
immunogenic one. In this light, it is perhaps more useful to think
of T cell allergic hypersensitivities versus autoimmunity as
involving a continuumof peptides from truly foreign ones through
various levels of modifications of self-peptides mediated by both
foreign and endogenous mechanisms.
EXPERIMENTAL PROCEDURES
More experimental details are in the Extended Experimental Procedures.
Protein Expression and Purification
All MHC proteins were expressed in baculovirus infected insect cells as solu-
ble proteins as previously described (Crawford et al., 1998; Dai et al., 2010). All
contained an antigenic peptide covalently attached via a C-terminal flexible
linker to the N terminus of the MHCII beta chain (Kozono et al., 1994). All
had a stabilizing C-terminal acid-base leucine zipper (O’Shea et al., 1993)
and a peptide tag for enzymatic biotinylation (Crawford et al., 1998), which
were removed proteolytically with either papain or thrombin for crystallog-
raphy and differential scanning fluorimetry.
The V domains of the AV22 TCR were cloned as previously described into a
bacterial expression vector in frame with sequence encoding the extracellular
portions of human Ca or Cb (Dai et al., 2008; Kjer-Nielsen et al., 2003). Inclu-
sion bodies containing the separate chains were prepared in Escherichia coli
BL21 Rosetta cells (EMD Biosciences). The solubilized proteins were mixed
and refolded as previously described (Dai et al., 2008; Kjer-Nielsen et al.,
2003).
T Cell Stimulation
A T cell transfectoma bearing the AV22 TCR (Bowerman et al., 2011) was stim-
ulated in culture alone or with various concentrations of BeSO4. The surface of
the culture wells had various biotinylated MHCII-peptide combinations
captured via Extravidin (Sigma). The extent of AV22 activation was assessed
by IL-2 in the culture supernatants after 24 hr (White et al., 2000).
Surface Plasmon Resonance
The ability of the soluble AV22 TCR to bind to various combinations of MHCII-
peptide with or without Be2+ was assessed with surface plasmon resonance
using a BIAcore 2000 instrument. The biotinylated MHCII-peptide (2,000
resonance units [RU]) was immobilized in flowcells of a streptavidin BIAsensor
chip and various concentrations of the soluble AV22 TCR injected before and
after exposure of the MHCII to 50 mM Be2+. Binding kinetics were calculated
using instrument software (BIAevaluation 4.1).
Differential Scanning Fluorimetry
The thermal stabilities of various MHCII-peptide complexes were determined
by differential scanning fluorimetry using either a Stratagene MX3005p
(Agilent) or CFX96 RCT-PCR (Bio-Rad) instrument. Proteins were mixed with
the dye SYPRO orange and the fluorescence of the dye bound to the protein
was followed as the temperature was increased from 20C to 100C. The
melting temperature (Tm) was defined as the temperature at which the fluores-
cence increase was 50% of the maximal increase.
Crystallography
Crystals grown in hanging or sitting drop chambers were cryopreserved in
liquid nitrogen. Diffraction data were collected at Brookhaven x25, APS 24
ID-C, and Berkley 822. Details of crystallization, cryopreservation, data collec-
tion, data processing, and model building and refinement are in the Supple-
mental Information and Table S1.
Structure Analysis and Representations
Atom-to-atom interactions between the AV22 TCR and DP2-M2-Be2+ were
calculated with the ncont program in the CCP4 program suite. Electrostatic
surface potential was calculated using PDB2PQR and APBS (Baker et al.,
2001; Dolinsky et al., 2004, 2007). Graphical representations of structures
were constructed with PyMOL, (PyMOL), WebLab Viewer Pro 4.1 (Accelrys),
and JMol (JMol).
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